Earnings call transcript: Evogene's Q2 2025 results reveal significant cost cuts

Evogene Ltd (EVGN) reported a wider-than-expected Q2 2025 net loss, with EPS of -$0.85 significantly missing the -$0.61 forecast and revenue of $880,000 falling short of the $1.69 million anticipation. Despite these misses, the stock experienced a modest 0.75% pre-market uptick, reflecting investor confidence in the company's aggressive cost reductions, including workforce streamlining and reduced R&D expenses, which lowered the net loss to $7.7 million. The firm is strategically pivoting to focus on its AI-driven Campus AI platform for pharmaceutical and agricultural applications, bolstered by recent asset sales that provide an 18-month operational runway and ongoing efforts to secure new collaborations.

Analysis

Evogene Ltd. (EVGN) reported a significant miss on its Q2 2025 financial forecasts, with an earnings per share of -$0.85, 39.34% below the expected -$0.61, and revenue of $880,000 falling 47.93% short of the $1.69 million projection. This underperformance is contrasted by a strategic overhaul focused on aggressive cost management and a pivot towards its proprietary 'Campus AI' platform. The company successfully reduced its net loss for the first half of the year to $7.7 million from $9.8 million year-over-year, driven by substantial cuts in R&D and sales expenses. Management has bolstered the balance sheet through a $4.4 million ATM offering and the sale of its Lavie Bio and MicroBoost AI assets to ICL, securing a stated operational runway of approximately 18 months. The market's muted positive reaction, a 0.75% pre-market stock increase, indicates that investors are currently prioritizing the company's forward-looking AI strategy and improved financial stability over the weak quarterly results. The company's future performance now heavily depends on leveraging its Campus AI platform to secure new collaborations in the pharmaceutical and agricultural sectors, with existing partnerships with Google, Bayer, and Corteva providing a foundation.

Key Decisions for Investors

• Investors should assess Evogene based on the execution of its strategic pivot to an AI-platform company, rather than its historical earnings misses, with the signing of new high-value collaboration agreements for its Campus AI being the primary validation metric.
• Carefully monitor the company's cash burn rate relative to its stated 18-month runway, as any delays in commercialization or partnership milestones could necessitate further dilutive financing.
• Consider that the current investment thesis is a high-risk turnaround play, where potential upside is contingent on future catalysts, including successful completion of the Biomica clinical trial by early 2026 and the ability of the Castera subsidiary to build a sustainable revenue stream.